Nektar Therapeutics’s NKTR share price has surged by 6.77%, which has investors questioning if this is right time to sell.

Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387 Phase 2/3 clinical trial ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL ... not respond to antitumor necrosis factor agents or ...

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Unrepresentative pre-clinical models contribute to poor translation of glioblastoma research. We present an ...

Tda1 protein kinase, activated by Snf1 and yeast GSK3-β, fine-tunes metabolism through the phosphorylation of Hxk2, which is ...

Network models are a computer architecture, implementable in either hardware or software, meant to simulate biological populations of interconnected neurons. These models, also known as ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...